---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-084156"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:37:23.108558+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Apellis adds Dr. Mikael Dolsten as independent Class I director

## Summary
- Dr. Mikael Dolsten elected to Apellis Board as Class I director effective March 1, 2026, serving until the 2027 annual meeting.
- Dolsten deemed independent under Nasdaq rules; no committee appointments at this time.
- Received initial equity grant: option with $300,000 Black-Scholes value (3-year vest) and RSUs worth $300,000 (1-year cliff vest).
- Standard indemnification agreement in place; no family relationships or transactions with the Company.

## SEC filing metadata
- accession: 0001193125-26-084156
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312526084156/0001193125-26-084156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312526084156/d115780d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-084156
- JSON: https://secwatch.observer/filing/0001193125-26-084156.json
- Plain text: https://secwatch.observer/filing/0001193125-26-084156.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.